세계의 동물용 백신 시장 규모는 2024년 99억 달러로 평가되었고, CAGR 6.9%를 나타내 2034년에는 190억 달러에 달할 것으로 예측되고 있습니다. 백신 접종 프로그램의 중요성은 배가 되고 있습니다. 예방 접종을 포함한 예방 헬스케어에 투자하는 경향이 강해지고 있습니다. 동시에, 축산 농가는 공급 체인을 마비시키고 국제 무역에 영향을 줄 수 있는 전염성이 높은 병으로부터 소군을 지키기 위해, 적극적인 예방 접종 전략을 채용하고 있습니다. 제도를 강화하고 동물의 복지를 지키고 식품 공급망을 확보하고 종을 넘은 질병 전파의 위험을 최소화하기 위해 강제 예방 접종 프로그램을 실시했습니다.
시장 세분화는 가축과 반려동물의 두 가지 주요 범주로 크게 나뉩니다. 가금류, 암소, 돼지, 수산 양식 등의 가축 종은 세계의 식량 안보와 농업 경제에 필수적입니다. 최소한으로 유지하기 위해 매우 중요합니다. 구제역, 돼지열, 조류독감의 발생은 이 분야에서는 여전히 심각한 우려 사항이며, 강력한 백신 전략의 필요성을 강하게 하고 있습니다.
| 시장 범위 | |
|---|---|
| 시작 연도 | 2024년 |
| 예측 연도 | 2025-2034년 |
| 시작 금액 | 99억 달러 |
| 예측 금액 | 190억 달러 |
| CAGR | 6.9% |
동물용 의약품 분야의 백신은 약독화 백신, 결합형 백신, 불활성화 백신, DNA 백신 등 여러 유형이 있습니다. 이러한 백신은 강력한 면역반응을 생산하고 장기적인 예방효과를 발휘하는 것으로 널리 지지되고 있습니다.
북미는 2024년 세계의 동물용 백신 시장의 40.6%를 차지했습니다. 소, 닭, 돼지로 구성된 농업 부문이 확립되어 있습니다.
세계의 동물용 백신 시장을 형성하는 주요 기업은 Zoetis, Merck Animal Health, Virbac, Boehringer Ingelheim International, Bioveta, Brilliant Bio Pharma, Dechra Pharmaceuticals, Vetoquinol, Neogen Corporation, Elanco Animal Health, Hipra Animal Health Limited Inc.) 등이 있습니다. 이러한 기업은 광범위한 조사 개발을 통해 백신 포트폴리오를 적극적으로 확대하고 있습니다. 스스로의 향상에 도움이 되고 있습니다. 또한 유전자 공학이나 재조합 DNA와 같은 첨단 기술의 채용에 의해 진화하는 질병의 위협에 맞춘, 보다 효과적이고 오래가는 백신의 개발이 가능하게 되어 있습니다.
The Global Animal Vaccines Market was valued at USD 9.9 billion in 2024 and is estimated to grow at a CAGR of 6.9% to reach USD 19 billion by 2034. The global demand for animal vaccines is on the rise as concerns over animal health and food safety gain increasing prominence. With the growing emphasis on preventing zoonotic diseases and reducing economic losses from animal disease outbreaks, the importance of vaccination programs has grown multifold. A steady rise in the global animal population, along with the increasing trend of pet adoption and ownership, is reshaping how veterinary care is perceived and prioritized. Pet owners today are more inclined to invest in preventive healthcare, including vaccinations, to ensure longer and healthier lives for their companion animals. At the same time, livestock farmers are adopting proactive immunization strategies to safeguard their herds against highly contagious diseases that can cripple supply chains and impact international trade. Governments across the globe are tightening regulations related to animal health, implementing compulsory vaccination programs to protect animal welfare, secure the food supply chain, and minimize the risk of cross-species disease transmission. This broader awareness of animal health as an integral part of public health is significantly contributing to market growth.
The animal vaccines market is broadly segmented into two key categories: livestock and companion animals. In 2024, the livestock category dominated the market with a valuation of USD 6.4 billion. Livestock species such as poultry, cattle, swine, and aquaculture are critical to global food security and agricultural economies. Preventing disease outbreaks in these animals is crucial to maintaining productivity and minimizing financial losses. Incidences of foot-and-mouth disease, swine fever, and avian influenza remain serious concerns in this sector, reinforcing the need for robust vaccination strategies. While the companion animal segment is also expanding due to rising pet ownership and increased attention to pet wellness, the livestock segment continues to generate the highest revenue.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $9.9 Billion |
| Forecast Value | $19 Billion |
| CAGR | 6.9% |
Vaccines in the animal health sector include several types, such as attenuated live, conjugate, inactivated, DNA, recombinant, and others. Among these, attenuated live vaccines held the highest market share in 2024, accounting for 44.1% of the total. These vaccines are widely favored for their ability to produce strong immune responses and deliver long-term protection. Their capability to stimulate both humoral and cell-mediated immunity often reduces the need for repeated doses, making them a preferred option in both livestock and companion animal vaccination programs.
North America accounted for 40.6% of the global animal vaccines market in 2024. This dominant share is driven by a large population of domesticated animals and livestock in the region. The United States leads in pet ownership and has a well-established agricultural sector comprising cattle, poultry, and swine. The ongoing focus on maintaining herd health and minimizing infectious disease risks continues to drive vaccine adoption in the region.
Key players shaping the global animal vaccine landscape include Zoetis, Merck Animal Health, Virbac, Boehringer Ingelheim International, Bioveta, Brilliant Bio Pharma, Dechra Pharmaceuticals, Vetoquinol, Neogen Corporation, Elanco Animal Health, Hipra Animal Health Limited, and Henry Schein Animal Health (Covetrus, Inc.). These companies are actively expanding their vaccine portfolios through extensive research and development. Strategic partnerships with veterinary organizations and government agencies are helping improve vaccine accessibility. Additionally, the adoption of advanced technologies like genetic engineering and recombinant DNA is enabling the creation of more effective, long-lasting vaccines tailored to evolving disease threats.